Results 191 to 200 of about 121,021 (313)

Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with a 5‐year survival rate of approximately 50%, secondary to their metastatic potential and resistance to therapy. MPNSTs can arise sporadically, as a late toxicity from therapeutic radiotherapy, or in patients with neurofibromatosis type 1 (NF1).
Rachel E. Aubrey, Pamela Psarianos, Anna T. Santiago, Anthony M. Griffin, Peter C. Ferguson, Abha A. Gupta, Hagit Peretz Soroka, David B. Shultz   +7 more
wiley   +1 more source

The diagnostic challenge of melanoma with myxoid change mimicking metastatic soft tissue sarcoma. [PDF]

Quant Imaging Med Surg
Ichikawa J, Ogawa Y, Kawasaki T, Fukushima Y, Wako M, Fujimaki T, Onohara K.   +6 more
europepmc   +1 more source

Evaluating referral patterns and treatment timeliness for soft tissue sarcoma in rural WA : insights from the WA state sarcoma service [PDF]

Ellen Maclean, Vindya Johnston, Chloe Price, Andrew Coveney, Rupert Hodder   +4 more
openalex   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma. [PDF]

Precis Clin Med
Wang D, Sun D, Tu J, Cui X, Qu L, Chen L, Zhang Z, Jiang Z, Li R, Xuan Z, Cui J, Sun X, Jia X, Liu P, Xiong Y, Wang J, Jiang Y, Liu B.   +17 more
europepmc   +1 more source

Multi-tyrosine kinase inhibitors in paediatric soft tissue sarcoma – A review [PDF]

Kim P.J. Schellekens, Andrea Ferrari, Michael T. Meister, C. Michel Zwaan, Susanne A. Gatz, Max M. van Noesel, Michela Casanova, Reineke A. Schoot   +7 more
openalex   +1 more source

Soft Tissue Sarcomas

Veterinary Quarterly, 1998
openaire   +2 more sources

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background We present the case of 72–year‐old male with metastatic de‐differentiated chondrosarcoma (“DDCS”). DDCS is a rare soft tissue cancer that carries a dismal prognosis in the metastatic stage, and is resistant to both traditional chemotherapy and radiotherapy. There is a distinct lack of proven systemic therapies. Case This case report
Matthew Youssef, Peter Grimison
wiley   +1 more source

Characteristics and Outcomes of Soft Tissue Sarcoma in Saudi Arabia: A 10-Year Experience. [PDF]

Cancer Manag Res
Alshamsan B, Alrifai OI, Altayeb MA, Alobud MM, Alshomrani A, Alsadoun NF, Bin Khidhr R, Pant R, Shaheen M, Atallah JP.   +9 more
europepmc   +1 more source

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

, 2017
Jennifer S. Carew, Claudia M. Espitia, Weiguo Zhao, Monica Mita, Alain C. Mita, Steffan T. Nawrocki   +5 more
openalex   +2 more sources